Injectable cabotegravir (CAB) and rilpivirine (RPV) long-acting is a new antiretroviral treatment (ART) option for HIV-1 infection in virologically suppressed people with HIV (PWH). The aim of this study is to describe the causes of long-acting (LA) CAB+RPV discontinuation in clinical practice.
Causes of discontinuation of long acting cabotegravir and rilpivirine in clinical practice. Results from the prospective multicenter SCOLTA cohort.
Giovanni Francesco Pellicanò;
2024-01-01
Abstract
Injectable cabotegravir (CAB) and rilpivirine (RPV) long-acting is a new antiretroviral treatment (ART) option for HIV-1 infection in virologically suppressed people with HIV (PWH). The aim of this study is to describe the causes of long-acting (LA) CAB+RPV discontinuation in clinical practice.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
